2.1. Analysis.
Comparison 2 ICS versus placebo, parallel‐group studies, greater than 2 months to 6 months (all doses), Outcome 1 Change in pre‐bronchodilator FEV1 compared with baseline.
Comparison 2 ICS versus placebo, parallel‐group studies, greater than 2 months to 6 months (all doses), Outcome 1 Change in pre‐bronchodilator FEV1 compared with baseline.